LOS ANGELES, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming February 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Bitdeer Technologies Group (“Bitdeer” or the “Company”) (NASDAQ: BTDR) securities between June 6, 2024 and November 10, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR BITDEER INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING C ...

James Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust and truly diversified portfolios that will continually preserve and increase wealth. The Pragmatic Investor covers global macro, international equities, commodities, tech and cryptocurrencies and is designed to guide investors of all levels in their journey. Features include a The Pragmatic Investor Portfolio, weekly market ...

Key Takeaways JBL beat Q1 estimates, posting $8.3B in revenue and non-GAAP EPS of $2.85 on strong year-over-year growth.JBL's Intelligent Infrastructure delivered 46% of revenues, surging 54% YoY on AI data center demand.JBL expects AI data centers, healthcare and automation to drive growth in 2026. Jabil, Inc. (JBL) reported strong first-quarter fiscal 2026 results, with both bottom and top lines surpassing the Zacks Consensus Estimate. The company reported a top-line expansion year over year, owing to hea ...

Key Takeaways FNB introduced Payment Switch to auto-transfer recurring ACH and debit card payments via its mobile app.Payment Switch complements Direct Deposit Switch, enabling near-real-time updates across multiple merchants.F.N.B. Corp ties Payment Switch to eStore onboarding and its omnichannel Clicks-to-Bricks strategy.F.N.B. Corp. (FNB) has introduced Payment Switch, a service that allows clients to automatically transfer their recurring Automated Clearing House (ACH) and debit card payments to FNB thr ...

Key Takeaways HRB has a Growth Score of A, with earnings projected to rise 6% in 2025 and 7.9% in 2026.H&R Block revenue growth is driven by higher U.S. assisted tax volumes and rising net average charges.H&R Block expands client engagement via Second Look, Spruc banking and AI-powered DIY tax tools.H&R Block (HRB) has a Growth Score of A, which condenses key financial metrics to reflect a fair sense of the quality and sustainability of its growth.The company’s earnings are expected to increase 6% in 2025 a ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it ...

The U.S. jobs market isn't so hot, investors learned this week, but inflation is hotter than anyone would like. Just how much? ...

On October 23, 2025, before the market opened, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, below prior expectations, and informed investors that it anticipated net sales growth of –2% to 2% and organic sales growth of 0% to 4% for 2026. During the accompanying earnings call, management revealed that sales of three new products were expected to decline in 2026—including two electrophysiology devices—and that market adoption of these products had been slow ...

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s ahead for MRK stock?The trial showed Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically significant and clinically meani ...

NVIDIA Corporation (NASDAQ:NVDA) is one of the stocks that Jim Cramer shared his take on. During the episode, Cramer said that he is not changing his “tune” around the company, as he said: “No matter what, though, I still believe in AI as the fourth industrial revolution, and I think most of these stocks will be worth buying once their valuations come down to less lofty levels. And of course, I’m including NVIDIA, which people ask me about all the time. And I say the same thing. I say, own it, don’t trade ...